Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ann Overy

Pediatrics Meridian, ID Doctor of Osteopathy

NPI 1306020086 CMS profile 798121

3280 E Lanark Dr, Meridian, ID 83642

Open in the dashboard

General payments

$945

56 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ann Overy of Meridian, ID is reported in the CMS Open Payments database as having received $945 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $197 11
2024 General $240 13
2023 General $334 20
2022 General $42 3
2020 General $11 1
2019 General $122 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ann Overy
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Ann Overy were reported at $197. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Ann Overy Pediatrics median Middle half National median
2019 $122 $86 $31–$183 $163
2020 $11 $49 $22–$110 $114
2021 $0 $68 $27–$158 $132
2022 $42 $77 $30–$173 $149
2023 $334 $88 $33–$190 $160
2024 $240 $94 $34–$206 $164
2025 $197 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $164 10 payments
  2. Ironshore Pharmaceuticals Inc. $138 7 payments
  3. Pfizer Inc. $134 8 payments
  4. Sanofi Pasteur Inc. $99 5 payments
  5. Merck Sharp & Dohme Corporation $76 5 payments
  6. AstraZeneca Pharmaceuticals LP $47 3 payments
  7. GlaxoSmithKline, LLC. $45 3 payments
  8. Janssen Pharmaceuticals, Inc $43 3 payments
  9. Exact Sciences Corporation $29 2 payments
  10. Philips Electronics North America Corporation $22 1 payment
  11. Other $147 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $945 56 payments
Products named General payments · program years 2019–2025
  1. JORNAY PM $138 7 payments
  2. RYBELSUS $114 7 payments
  3. Ozempic $114 7 payments
  4. PREVNAR 20 $107 6 payments
  5. TRUMENBA $91 5 payments
  6. PENBRAYA $76 4 payments
  7. COMIRNATY $66 4 payments
  8. BEYFORTUS $65 3 payments
  9. Wegovy $51 3 payments
  10. GARDASIL 9 $48 3 payments
  11. Other $833 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record